MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cellectis SA Company Profile (NASDAQ:CLLS)

Consensus Ratings for Cellectis SA (NASDAQ:CLLS) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $47.80 (79.63% upside)

Analysts' Ratings History for Cellectis SA (NASDAQ:CLLS)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016Ladenburg ThalmannInitiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016SunTrustInitiated CoverageBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Bank of AmericaInitiated CoverageBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2015Jefferies GroupInitiated CoverageBuy$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Cellectis SA (NASDAQ:CLLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016Q116($0.35)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2016Q415($0.30)$0.65ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/19/2015Q215($0.43)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cellectis SA (NASDAQ:CLLS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.56)($0.43)($0.50)
Q2 20163($0.65)($0.44)($0.55)
Q3 20163($0.65)($0.45)($0.56)
Q4 20163($0.65)($0.46)($0.57)
(Data provided by Zacks Investment Research)
Dividend History for Cellectis SA (NASDAQ:CLLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cellectis SA (NASDAQ:CLLS)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Cellectis SA (NASDAQ:CLLS)
DateHeadline
06/23/16 10:35 PMCellectis S.A. (CLLS) Updated Price Targets - FTSE News
06/20/16 04:59 PMCellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) - [at noodls] - e6e9713c-2a4a-4dd8-96d1-0ed783d1afea.pdf PRESS RELEASE New York, N.Y. - June 20, 2016 - Cellectis (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based ...
06/20/16 01:13 PMETF’s with exposure to Cellectis SA : June 20, 2016 -
06/13/16 02:42 PMEarnings to Watch: Digital Turbine, Inc. (NASDAQ:APPS), Cellectis S.A. (NASDAQ:CLLS), MV Oil Trust (NYSE:MVO ... - KC Register
06/05/16 11:03 AMAfter Last Week What Do Analysts Think Of Cellectis S.A. (CLLS) - Share Trading News
06/04/16 11:49 AMCellectis SA's (CLLS) “Buy” Rating Reaffirmed at Oppenheimer - Let Me Know About This
06/03/16 03:25 PMBuy, Sell Or Hold Rating For Cellectis S.A. (CLLS)? - Share Trading News
06/03/16 02:13 PMETF’s with exposure to Cellectis SA : June 3, 2016 -
06/01/16 03:23 PMCellectis S.A. (CLLS) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Cellectis S.A. (CLLS) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Cellectis S.A. (CLLS). The latest reports which are currently in issue on Wednesday 1st of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
06/01/16 11:49 AMCellectis SA :CLLS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/30/16 10:41 PMCellectis SA (CLLS) Earns Buy Rating from Piper Jaffray - Let Me Know About This - Cellectis SA (CLLS) Earns Buy Rating from Piper JaffrayLet Me Know About ThisCellectis SA logo Cellectis SA (NASDAQ:CLLS)'s stock had its “buy” rating reaffirmed by equities researchers at Piper Jaffray in a report issued on Sunday. Cellectis SA (NASDAQ:CLLS) traded down 1.55% during mid-day trading on Friday, hitting $31.22.Next Weeks Broker Price Targets For Cellectis S.A. (CLLS)Share Trading Newsall 2 news articles »
05/30/16 12:34 PMNext Weeks Broker Price Targets For Cellectis S.A. (CLLS) - Share Trading News - Next Weeks Broker Price Targets For Cellectis S.A. (CLLS)Share Trading News03/02/2016 – SunTrust began new coverage on Cellectis S.A. giving the company a “buy” rating. They now have a USD 35 price target on the stock. 02/29/2016 – Cellectis S.A. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have ...
05/23/16 04:00 PMCalyxt Appoints Federico A. Tripodi to New Role of CEO - [Business Wire] - Calyxt, Inc., a Minnesota-based company developing healthier food products to benefit both consumers and growers, announced today the appointment of former Monsanto Corporation executive Federico A.
05/19/16 05:02 PMCellectis S.A. Reports Results from Shareholders’ General Meeting Held on May 17, 2016 - [at noodls] - 1715839e-ddad-4234-8e8d-c6b078c8d7f9.pdf PRESS RELEASE Cellectis S.A. Reports Results from Shareholders' General Meeting Held on May 17, 2016 New York, May 19, 2016 - Cellectis S.A. Shareholders' General ...
05/11/16 06:07 PMCellectis Reports First Quarter 2016 Financial Results - [at noodls] - d62cf528-78f9-4bce-9f3d-982fa52c9cc9.pdf PRESS RELEASE - Initiated UCART123 GMP production concept - Secured strategic supply of key materials for GMP manufacturing - Strong cash position of $315 million ...
05/11/16 06:07 PMFirst Quarter 2016 Financial Results - [at noodls] - 9d972143-29b0-4be7-a78a-93219d79d119.pdf UNITED STATES‌ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities ...
05/09/16 05:41 AMCellectis' gene editing breakthrough: CEO -
05/06/16 07:14 PMAACR Posters 2016 - [at noodls] - 434b933e-e077-4871-be48-dcab847424ef.pdf Allogeneic TCR/CS1 double knockout T-­‐cells bearing an an9-­‐CS1 chimeric an9gen receptor: An improved immunotherapy approach for the treatment of Mul9ple Myeloma ...
05/06/16 06:14 PMASGCT Posters 2016 - [at noodls] - debc7ab4-ac00-403f-b90a-eeb3313718c7.pdf u Integra0on of Dual Signal Input Strategies in Novel Chimeric An0gen Receptors to Control the CAR T-­‐Cell Func0ons Alexandre Juillerat, Alan Marechal, Jean Marie ...
05/02/16 04:20 PMCellectis to Present Data on its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting - [at noodls] - ac67e175-7d36-415d-84e5-4d4a51a6d18a.pdf PRESS RELEASE Cellectis to Present Data on its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting May the 2nd, 2016 ...
04/28/16 11:24 AMConsolidated financial statements - Year ended December 31, 2015 - [at noodls] - b9cf3604-3b4d-401e-a4ae-aa1e9ec55ff8.pdf JMH CONSEIL ERNST & YOUNG et Autres This is a free translation into English of the statutor y auditors' report on the consolidated financial statements issued in ...
03/25/16 12:04 PMCELLECTIS S.A. Financials -
03/21/16 04:54 PMCellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc. - [at noodls] - 58639e23-5605-4c42-bb08-d43737ae9f48.pdf PRESS RELEASE New York, March 21, 2016 - Cellectis (Alternext: ALCLS - Nasdaq Global Market: CLLS), a biopharmaceutical company focused on developing immunotherapies ...
03/02/16 01:48 PMCellectis SA (ADR) (CLLS) is Initiated by Sun Trust Rbsn Humphrey to Buy - Los Angeles Mirror - Cellectis SA (ADR) (CLLS) is Initiated by Sun Trust Rbsn Humphrey to BuyLos Angeles MirrorCellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research development and commercialization of rational genome engineering technologies. It has developed an ...and more »
03/02/16 06:41 AMCoverage initiated on Cellectis by Sun Trust Rbsn Humphrey -
03/01/16 08:00 PMCellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility - [Business Wire] - Regulatory News:
02/28/16 01:19 PMCellectis SA Ads (NASDAQ:CLLS) Sellers Increased By 11.35% Their Shorts - Business Standard Tribune - Cellectis SA Ads (NASDAQ:CLLS) Sellers Increased By 11.35% Their ShortsBusiness Standard TribuneThe stock of Cellectis SA Ads (NASDAQ:CLLS) registered an increase of 11.35% in short interest. CLLS's total short interest was 1.39M shares in February as published by FINRA. Its up 11.35% from 1.25 million shares, reported previously. With 155,800 ...
02/24/16 01:47 PMCellectis SA Ads (NASDAQ:CLLS) Shorts Decreased by 2.07% After Short Covering - Clinton Financial - Cellectis SA Ads (NASDAQ:CLLS) Shorts Decreased by 2.07% After Short CoveringClinton FinancialThe stock of Cellectis SA Ads (NASDAQ:CLLS) registered a decrease of 2.07% in short interest. CLLS's total short interest was 1.25 million shares in February as published by FINRA. Its down 2.07% from 1.28M shares, reported previously. With 176,700 ...
02/22/16 01:26 PMUpdated Price Targets On Cellectis S.A. (CLLS) - Risers & Fallers - Updated Price Targets On Cellectis S.A. (CLLS)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Cellectis S.A. (CLLS). The latest broker reports which are currently outstanding on Monday 22nd of February state 3 analysts have a rating of “strong buy”, 1 analysts “buy ...Zacks: Brokerages Set $56.00 Price Target for Cellectis SA (NASDAQ:CLLS)Financial Market NewsStock Highlights: Cellectis S.A. (NASDAQ:CLLS), Graphic Packaging Holding Company (NYSE:GPK), Stage Stores ...KC Registerall 3 news articles »
02/18/16 01:22 PMCellectis SA (ADR) (NASDAQ:CLLS) announced that it entered into a new agreement for the cGMP manufacturing of ... - Inside Trade - Cellectis SA (ADR) (NASDAQ:CLLS) announced that it entered into a new agreement for the cGMP manufacturing of ...Inside TradeCellectis SA (ADR) (NASDAQ:CLLS) announced that it entered into a new agreement for the cGMP manufacturing of UCART123 clinical batches, Cellectis' lead product candidate, with CELLforCURE, an LFB group company and the largest industrial facility ...
02/16/16 01:35 PMCellectis SA (ADR) (CLLS) Stock Surges 18% – Why is this stock up so much? - Independent Reporter - Cellectis SA (ADR) (CLLS) Stock Surges 18% – Why is this stock up so much?Independent ReporterShares of Cellectis SA (ADR) (NASDAQ:CLLS) have jumped 18.25% to $23.00 in pre-market trading this morning, even though the company did not release any news. Specializing in creating T-cells which have memories that allow them to attack cancer cells ...Cellectis Up More Than 19% As Director And Other Business Entities Acquire 3.3 Million Shares, 9.42% Stake ...WallStreet.orgall 2 news articles »
02/13/16 01:31 PMCellectis SA Ads (NASDAQ:CLLS) Sellers Covered 2.07% of Their Shorts - fdanewsalert.com - Cellectis SA Ads (NASDAQ:CLLS) Sellers Covered 2.07% of Their Shortsfdanewsalert.comThe stock of Cellectis SA Ads (NASDAQ:CLLS) registered a decrease of 2.07% in short interest. CLLS's total short interest was 1.25M shares in February as published by FINRA. Its down 2.07% from 1.28M shares, reported previously. With 176,700 shares ...
02/11/16 01:31 PMLatest Analysts Reports On Cellectis S.A. (CLLS) - Risers & Fallers - Latest Analysts Reports On Cellectis S.A. (CLLS)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Cellectis S.A. (CLLS). The latest broker reports which have been released state 3 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...
02/09/16 01:03 PMCellectis SA Ads (NASDAQ:CLLS) Shorted Shares Increased 0.11% After Market Selling - fdanewsalert.com - Cellectis SA Ads (NASDAQ:CLLS) Shorted Shares Increased 0.11% After Market Sellingfdanewsalert.comThe stock of Cellectis SA Ads (NASDAQ:CLLS) registered an increase of 0.11% in short interest. CLLS's total short interest was 1.28M shares in February as published by FINRA. Its up 0.11% from 1.28 million shares, reported previously. With 197,300 ...
02/01/16 01:02 PMCompany Shares of Cellectis S.A. (NASDAQ:CLLS) Drops by -6.4% - Bull Report - Company Shares of Cellectis S.A. (NASDAQ:CLLS) Drops by -6.4%Bull ReportCellectis S.A. (NASDAQ:CLLS) has lost 6.4% during the past week and dropped 27.94% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 8.01%. Cellectis S.A. (NASDAQ:CLLS) has ...
01/25/16 01:14 PMCompany Shares of Cellectis S.A. (NASDAQ:CLLS) Rally 4.87% - The Daily Rover - Company Shares of Cellectis S.A. (NASDAQ:CLLS) Rally 4.87%The Daily RoverShares of Cellectis S.A. (NASDAQ:CLLS) appreciated by 4.87% during the past week but lost 22.81% on a 4-week basis. The shares have outperformed the S&P 500 by 3.41% in the past week but underperformed the index by 16.57% in the last 4 weeks.
01/19/16 05:15 PMCellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies - [at noodls] - cde2f40b-ea3c-4911-99a7-0619923b68bb.pdf PRESS RELEASE Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies January 19, 2016 - New ...
01/19/16 04:07 PM5:07 pm Cellectis enters into new agreement with CELLforCURE for the cGMP manufacturing of UCART123 -
01/18/16 09:01 AMBiotech investor: 'None of us were as smart as we thought we were' -
01/14/16 11:11 AMA biotech venture capitalist explains his 3 criteria for new investments -
01/13/16 01:28 PMDoctors might one day treat cancer by cutting bad DNA out of your genes -
01/11/16 04:49 PMCellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions - [at noodls] - 8af0c0cc-497f-4f5e-9332-92f29986c68f.pdf PRESS RELEASE Cellectis Announces a New CAR Architecture Controlling CAR T- Cell Functions Publication in Scientific Reports, a Nature Publishing Group Journal ...
01/07/16 05:02 PMCellectis Announces Chief Medical Officer Appointment to Senior Leadership Team - [at noodls] - 5fbf937d-9c9b-466d-9bcd-acf1c93f4f72.pdf PRESS RELEASE New York, January 7, 2016 - Cellectis (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on ...
12/23/15 04:59 PMCellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies - [at noodls] - f243b009-6af7-4449-98c7-9a4b1e3b06a2.pdf PRESS RELEASE Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies New York, ...
12/23/15 05:00 AMJim Cramer's Top Takeaways: Paychex and Cellectis -
12/21/15 05:08 PMCellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016 - [at noodls] - 79da31bc-92f7-4248-9de0-ce101b8ef8f6.pdf PRESS RELEASE New York, December 21, 2015 - Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a biopharmaceutical company focused on developing immunotherapies based ...
12/03/15 05:41 PMCellectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier - [at noodls] - 158e21dc-f4eb-4ce3-a69f-38f41450fa04.pdf PRESS RELEASE December 3, 2015 - Cellectis (Alternext: ALCLS - Nasdaq: CLLS) will host a conference call with Pfizer Inc. (PFE) and Servier on Monday, December ...
12/02/15 07:02 AMBlood-Cancer Fighters To Strut Their Stuff At ASH -
12/01/15 03:45 PM15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare Conference -
About Cellectis SA

Cellectis SA logoCellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLLS
  • CUSIP:
Key Metrics:
  • Previous Close: $26.61
  • 50 Day Moving Average: $30.36
  • 200 Day Moving Average: $27.08
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $937.42M
  • Current Quarter EPS Consensus Estimate: $-2.10 EPS
Additional Links:
Cellectis SA (NASDAQ:CLLS) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha